人类肿瘤基因组学和斑马鱼模型研究发现缺失是黏膜黑色素瘤的驱动因素。
Human tumor genomics and zebrafish modeling identify loss as a driver of mucosal melanoma.
机构信息
Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
出版信息
Science. 2018 Nov 30;362(6418):1055-1060. doi: 10.1126/science.aau6509. Epub 2018 Nov 1.
Melanomas originating from mucosal surfaces have low mutation burden, genomic instability, and poor prognosis. To identify potential driver genes, we sequenced hundreds of cancer-related genes in 43 human mucosal melanomas, cataloging point mutations, amplifications, and deletions. The gene, which encodes a negative regulator of mitogen-activated protein kinase (MAPK) signaling, was inactivated in 37% of the tumors. Four distinct genotypes were associated with loss. Using a rapid, tissue-specific CRISPR technique to model these genotypes in zebrafish, we found that functions as a tumor suppressor, particularly in the context of mutations. knockdown caused MAPK activation, increased cell proliferation, and conferred resistance to drugs inhibiting KIT tyrosine kinase activity. These findings provide a rationale for MAPK inhibition in SPRED1-deficient melanomas and introduce a zebrafish modeling approach that can be used more generally to dissect genetic interactions in cancer.
起源于黏膜表面的黑色素瘤突变负担低、基因组不稳定且预后不良。为了鉴定潜在的驱动基因,我们对 43 个人类黏膜黑色素瘤中的数百个与癌症相关的基因进行了测序,对这些基因的点突变、扩增和缺失进行了分类。该基因编码丝裂原活化蛋白激酶(MAPK)信号的负调节剂,在 37%的肿瘤中失活。与 缺失相关的有四种不同的基因型。使用一种快速、组织特异性的 CRISPR 技术在斑马鱼中模拟这些基因型,我们发现 SPRED1 作为一种肿瘤抑制因子发挥作用,尤其是在 突变的情况下。SPRED1 敲低导致 MAPK 激活、细胞增殖增加,并赋予对抑制 KIT 酪氨酸激酶活性的药物的耐药性。这些发现为 SPRED1 缺陷型黑色素瘤中 MAPK 抑制提供了依据,并引入了一种斑马鱼建模方法,可更广泛地用于解析癌症中的遗传相互作用。